ArticleScientific reports2015
The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson's disease.Cell stem cell · 2025Article
- Material surface conjugated with fibroblast growth factor-2 for pluripotent stem cell culture and differentiation.Regenerative biomaterials · 2025Article
- Chromosomal quality control in hPSCs: A practical guide to SNP array analysis with GenomeStudio.Frontiers in cell and developmental biology · 2025Article
- Article
- Harnessing bioengineered myeloid progenitors for precision immunotherapies.NPJ Regenerative medicine · 2023Review
- Generation of 3D retinal tissue from human pluripotent stem cells using a directed small molecule-based serum-free microwell platform.Scientific reports · 2022Article
- Whole-genome analysis of human embryonic stem cells enables rational line selection based on genetic variation.Cell stem cell · 2022Article
- Nanopore Sequencing Indicates That Tandem Amplification of Chromosome 20q11.21 in Human Pluripotent Stem Cells Is Driven by Break-Induced Replication.Stem cells and development · 2021Article
- NRLStem cells (Dayton, Ohio) · 2021Article
- Transplantation of GMP-grade human iPSC-derived retinal pigment epithelial cells in rodent model: the first pre-clinical study for safety and efficacy in China.Annals of translational medicine · 2021Article
- Emulating Human Tissues and Organs: A Bioprinting Perspective Toward Personalized Medicine.Chemical reviews · 2020Review
- Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders.Noro psikiyatri arsivi · 2020Article
- Article
- Cryopreservation of Human Midbrain Dopaminergic Neural Progenitor Cells Poised for Neuronal Differentiation.Frontiers in cell and developmental biology · 2020Article
- SALL3 expression balance underlies lineage biases in human induced pluripotent stem cell differentiation.Nature communications · 2019Article
- iPS-Cell Technology and the Problem of Genetic Instability-Can It Ever Be Safe for Clinical Use?Journal of clinical medicine · 2019Review
- Developing defined substrates for stem cell culture and differentiation.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- Generation of Functioning Nephrons by Implanting Human Pluripotent Stem Cell-Derived Kidney Progenitors.Stem cell reports · 2018Article
- High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos.Stem cell research & therapy · 2017Article
- Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies.Molecular therapy. Methods & clinical development · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson's, Huntington's, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.